Monographie - Bortezomib

Ultimele actualizari :
23/04/2025

Bortezomib

Formula chimica

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bemoncaz	Mexic
Bicavan	Chilli
Biemib	Turcia
Borater	Argentina
Borcade	Turcia
Bormib	Argentina
Bortezomib	Argentina, Belgia, Brazilia, Chilli, Croatia, Danemarca, Ecuador, Elvetia, Finlanda, Franta, Germania, Irlanda, Italia, Luxemburg, Marea Britanie, Norvegia, noua Zeelandă, Peru, Romania, Slovenia, Spania, Ungaria
Bortrac	Ecuador, Peru
Bortzo	Peru
Botemib	Chilli, Ecuador, Peru
Bozix	Chilli, Peru
Bozob	Argentina, Chilli, Ecuador, Peru
Bromadene	Argentina
Egybort	India
Elomaziv	Mexic
Gysatri	Argentina
Miasoma	Argentina
Multizom	Argentina
Velcade	Arabia Saudita, Argentina, Austria, Belgia, Canada, Chilli, Columbia, Croatia, Danemarca, Ecuador, Egipt, Elvetia, Emiratele Arabe Unite, Finlanda, Franta, Germania, Grecia, Irlanda, Islanda, Italia, Japonia, Luxemburg, Malaezia, Mexic, Norvegia, noua Zeelandă, Olanda, Polonia, Portugalia, Romania, Slovenia, Spania, SUA, Suedia, Tunisia, Turcia, Ungaria, Venezuela
Velcord	Peru
Vortemyel	Croatia, Romania
Zefra	Argentina
Zegomib	Ungaria
Zuricade	Mexic

Bibliografie : Bortezomib

	tip	publicare
1911	Laborator	Bortezomib (Velcade®) - Summary of Product Characteristics Janssen-Cilag Ltd 2016
2010	ziar	André P, Cisternino S, Chiadmi F, Toledano A, Schlatter J, Fain O, Fontan JE. Stability of bortezomib 1 mg/ml solution in plastic syringe and glass vial. Ann Pharmacotherapy 2005 ; 39: 1462-1466.
2011	ziar	Friess D, Nguyen HC, Lipp HP. HPLC-stabilitätuntersuchungen zu rekonstituierten Bortezomib-Lösungen. Krankenhauspharmazie 2005 ; 26, 6: 206-210.
2232	ziar	Walker SE, Milliken D, Law S. Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4°C and Room Temperature (23°C) Can J Hosp Pharm 2008 ; 61, 1: 14-20.
3190	ziar	Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC, Pagliuca R, Mazzarelli V, Ottiero M, Scalfaro M, An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. Advance in Haematology 2009 Article ID 704928, 5 page
3240	poster	Perissutti M, Vigneron J, Zenier H, May I, Demoré B. Etude de la stabilité d'une solution de bortézomib à 1 mg/mL conditionnée en seringue de polypropylène. Congrès SFPO 2011
3337	ziar	Carati D, Masini C, Minguzzi M, Petocchi B, Romanazzi C, Rondoni C, Sangiorgi E, Sferra S, Simonetta S, Stancari A, Locchi F, Z Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4 °C and room temperature. EJHP 2012 ; 19: 428-431.
3349	ziar	Bosch-Ojeda C, Sanchez-Rojas M.F, Espinosa-Bosch M. Chemical stability of bortezomib solutions in original manufacturer vials. Int J Pharm Bio Sci 2012 ; 2, 3: 344-350.
3418	ziar	Berruezo garcia J, Espinosa Bosch M, Sanchez Rojas F, Bosch Ojeda C Chemical stability of bortezomib solutions in original manufacturer vial at room temperature and in syringe at 4°C. Int J Pharm Bio Sci 2013 ; 3, 1: 449-458.
3447	poster	Giovanelli M, Vigneron J, May I, Nicolas A. Etude de la stabilité d’une solution de bortézomib à 2,5 mg/mL par chromatographie liquide à haute performance couplée à un détecteur à barrettes de diodes et à un détecteur évaporatif à diffusion de lumière. SFPO Congress, Mandelieu, France 2013
3537	ziar	Lipp HP, Gfrörer W, Riedmüller S. Bortezomib zur subkutanen Applikation. Krankenhauspharmazie 2013 ; 34,11: 500-505.
3688	ziar	Walker S.E, Charbonneau L.F, Law S. Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C). Can J Hosp Pharm 2014 ; 67, 2: 102-107
4137	ziar	Patel T, Sewell G. Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare). Newsletter Stabilis 2018 41;2-6
4485	ziar	Law S, Charbonneau L, Iazetta J, Perks W, Ma N, Walker S.E. Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored 4°C and Room Temperature (23°C) Can J Hosp Pharm 2021 ;74;1:57-69

Mentions Légales